March 22, 2024Cancer Research

Armoring Mesothelin CAR-T Cells with PD-1 Blockade for Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Authors

ZZZhixiang ZhangSouth China Agricultural University JHJingwei HuangWuXi AppTec (China)ZZZhifeng ZhaoHebei Medical University

Discussion

Member takes

Implication

Preclinical evaluation shows membrane-bound PD-1 blockade enhances CAR-T cytotoxicity in pancreatic cancer models, highlighting a viable method against solid tumors.

Key Points

Armoring mesothelin-targeted CAR-T cells with a membrane-bound PD-1 antibody sustains long-term target killing, overcoming tumor immunosuppression.
AsPC-1 tumor cells markedly upregulate PD-L1 within 4 hours of IFN-γ exposure, whereas armored CAR-T cells retain robust cytotoxicity in vitro.
In vivo pancreatic cancer assays show increased tumor infiltration alongside enhanced anti-tumor activity; preclinical model limits apply.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e72ce5b6db6435876a6de2 https://doi.org/10.1158/1538-7445.am2024-6335

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation shows membrane-bound PD-1 blockade enhances CAR-T cytotoxicity in pancreatic cancer models, highlighting a viable method against solid tumors.

Armoring Mesothelin CAR-T Cells with PD-1 Blockade for Pancreatic Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Armoring Mesothelin CAR-T Cells with PD-1 Blockade for Pancreatic Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider